The group’s 2021 turnover stood at RON562 million (EUR114.2 million).
„For 2023, we expect the market to grow by 10-15% from 2022,” Daniela Ciulei, Bioeel CEO, told ZF Transilvania.
Bioeel is a privately held company active since 1992 through drug and cosmetics production.
The company expanded beyond production and has come to import and distribute pharmaceutical products for several local and international pharma companies.
Bioeel has its own distribution network and its own brand.
The company invested around RON3.3 million in equipment, technology, digitalization and security last year. For 2023, it has budgeted RON4.5 million investments and it also plans to complete the acquisition of a logistic center of around 4,000 square meters.
Bioeel group ended 2022 with 282 employees and plans to recruit further in 2023.
(English version by Catalina Apostoiu)